RT Journal Article
SR Electronic
T1 Amplicon-based nanopore minion sequencing of patients with COVID-19 omicron variant from India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268364
DO 10.1101/2021.12.27.21268364
A1 Kumar, Somesh
A1 Lomash, Avinash
A1 Faruq, Mohammed
A1 Siddiqui, Oves
A1 Kumar, Suresh
A1 Kapoor, Seema
A1 Suravajhala, Prashanth
A1 Polipalli, Sunil K
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.27.21268364.abstract
AB SARS-CoV-2 infection has been playing havoc with emerging omicron variants of concern (VoC). Here, we report sequencing of the omicron variant in 13 patients from India using Oxford Nanopore Technology (ONT) Minion, wherein a rapid amplicon based sequence analysis was performed to assess and compare with existing 34 mutations in spike glycoprotein. We highlight and discuss the nature of these mutations that are unique and common to other populations. This is perhaps the first report on omicron variants from India using a long read sequencing chemistry.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://nanoporetech.com/covid-19 Funding StatementThe authors gratefully acknowledge funding from Government of DelhiAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors gratefully acknowledge Institutional Ethics Committee of Maulana Azad Medical College, Delhi, India for granting the clearance of the study (F.1/IEC/MAMC/85/03/2021) . I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll omicron variant samples have been uploaded to GISAID.org with hCoV-19/India/un-LNHDXX/2021 series https://www.gisaid.org/